Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials

Koushik Paul, Niranjan Sathianathen, Philipp Dahm, Chap Le, Badrinath R. Konety

Research output: Contribution to journalArticle

Abstract

We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. reproduction of this article is prohibited.

Original languageEnglish (US)
Pages (from-to)385-390
Number of pages6
JournalJournal of Urology
Volume202
Issue number2
DOIs
StatePublished - Aug 1 2019

Fingerprint

Neoplasms
Industry
Urologic Neoplasms
Kidney Neoplasms
Information Storage and Retrieval
Testicular Neoplasms
Urinary Bladder Neoplasms
Reproducibility of Results
African Americans
Reproduction
Registries
Colorectal Neoplasms
Lung Neoplasms
Prostatic Neoplasms
Randomized Controlled Trials
Logistic Models
Regression Analysis
Clinical Trials
Breast Neoplasms

Keywords

  • African Americans
  • clinical trial protocols as topic
  • registries
  • research design
  • urogenital neoplasms

PubMed: MeSH publication types

  • Journal Article

Cite this

Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials. / Paul, Koushik; Sathianathen, Niranjan; Dahm, Philipp; Le, Chap; Konety, Badrinath R.

In: Journal of Urology, Vol. 202, No. 2, 01.08.2019, p. 385-390.

Research output: Contribution to journalArticle

@article{798cdfbb80df48c190703561a8b50dab,
title = "Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials",
abstract = "We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63{\%} reported sufficient accrual by time of closure and 58{\%} reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95{\%} CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95{\%} CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49{\%} vs 3.18{\%}, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. reproduction of this article is prohibited.",
keywords = "African Americans, clinical trial protocols as topic, registries, research design, urogenital neoplasms",
author = "Koushik Paul and Niranjan Sathianathen and Philipp Dahm and Chap Le and Konety, {Badrinath R.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1097/JU.0000000000000294",
language = "English (US)",
volume = "202",
pages = "385--390",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials

AU - Paul, Koushik

AU - Sathianathen, Niranjan

AU - Dahm, Philipp

AU - Le, Chap

AU - Konety, Badrinath R.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. reproduction of this article is prohibited.

AB - We performed a multiregistry analysis to assess relative differences in accrual sufficiency and race/ethnicity reporting in trials of common urological cancers and other nonurological solid organ tumors.Materials and Methods:We queried ClinicalTrials.gov and the ISRCTN (International Standard Randomised Controlled Trial Number) Registry for closed phase III and IV trials focused on prostate, colorectal, kidney, bladder, testicular, breast and lung cancer. Identified trials were cross-verified with appropriate published data sources. Comparative accrual sufficiency and rates of race/ethnicity reporting were calculated. Multivariable logistic regression analysis was performed to determine factors associated with accrual status and race/ethnicity reporting.Results:A total of 326 trials were identified based on our prespecified criteria, of which 63% reported sufficient accrual by time of closure and 58% reported data by race/ethnicity. Nonurological trials were significantly more likely to mention race data than urological trials (OR 3.25, 95% CI 1.24-8.55, p = 0.02). Industry sponsored trials were more likely to meet accrual targets than government funded projects (OR 5.44, 95% CI 1.64-18.20, p = 0.001). Although funding source did not influence race reporting, the reported recruitment of participants of African ethnicity was lower in industry sponsored trials (11.49% vs 3.18%, p <0.01). Two-thirds of the studies did not report baseline characteristics by African American race/ethnicity.Conclusions:Insufficient accrual and inadequate race/ethnicity reporting are prevalent issues, limiting interpretation of the results of clinical trials of major solid organ malignancies. Addressing these shortcomings would enhance result validity by raising statistical power and improving the transparency of reporting to better evaluate the generalizability of results. reproduction of this article is prohibited.

KW - African Americans

KW - clinical trial protocols as topic

KW - registries

KW - research design

KW - urogenital neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85069296282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069296282&partnerID=8YFLogxK

U2 - 10.1097/JU.0000000000000294

DO - 10.1097/JU.0000000000000294

M3 - Article

C2 - 31074679

AN - SCOPUS:85069296282

VL - 202

SP - 385

EP - 390

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -